Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Flotetuzumab as salvage therapy for primary induction failure and early AML

Ibrahim Aldoss • 11 Feb 2021
TCT 2021
Acute Myeloid Leukemia Leukemia Flotetuzumab

Ibrahim Aldoss, MD, City of Hope National Medical Center, Duarte, CA, discusses updated results of the first-in-human study of flotetuzumab, an investigational CD123 x CD3 bi-specific product currently in development for patients with acute myeloid leukemia (AML). Flotetuzumab has demonstrated encouraging activity in patients with primary induction failure and early relapse AML, which represents a population with poor prognosis and unmet need. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Ibrahim Aldoss

4:06
AUGMENT-101 trial: revumenib in patients with R/R KMT2Ar acute leukemia
Ibrahim Aldoss • 11 Dec 2023
5:05
Outcomes of alloHCT in adults with Ph-like ALL
Ibrahim Aldoss • 11 Feb 2021

Related Videos

1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals